Cyclacel Pharmaceuticals : January 2022 Corporate Presentation
January 04, 2022 at 03:59 pm
Share
Translating cancer biology into medicines
Corporate Presentation January 2022
Disclaimer
This presentation contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 about financial results and estimates, business strategy, clinical trial plans and research and development programs of Cyclacel Pharmaceuticals, Inc. By their nature, forward- looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future and are generally preceded by terms such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "potential," and similar expressions (including the negative thereof). For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent registration statement on Form S-1, most recent Annual Report on Form 10-K and other periodic and current filings that have been filed with the Securities and Exchange Commission and are available at www.sec.gov. The information in this presentation is current as of this date. Cyclacel does not take any responsibility to update such information.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Cyclacel Pharmaceuticals Inc. published this content on 04 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 January 2022 15:58:05 UTC.
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.